Analyst Valuation and EPS Growth for CNS Pharmaceuticals (NASDAQ:CNSP)

0
282

Earnings results for CNS Pharmaceuticals (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc. is estimated to report earnings on 11/30/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.

Analyst Opinion on CNS Pharmaceuticals (NASDAQ:CNSP)

2 Wall Street analysts have issued ratings and price targets for CNS Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.00, predicting that the stock has a possible upside of 358.33%. The high price target for CNSP is $11.00 and the low price target for CNSP is $11.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Dividend Strength: CNS Pharmaceuticals (NASDAQ:CNSP)

CNS Pharmaceuticals does not currently pay a dividend. CNS Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: CNS Pharmaceuticals (NASDAQ:CNSP)

In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock. Only 8.70% of the stock of CNS Pharmaceuticals is held by insiders. Only 0.56% of the stock of CNS Pharmaceuticals is held by institutions.

Earnings and Valuation of CNS Pharmaceuticals (NASDAQ:CNSP

Earnings for CNS Pharmaceuticals are expected to decrease in the coming year, from ($0.50) to ($0.53) per share. The P/E ratio of CNS Pharmaceuticals is -8.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of CNS Pharmaceuticals is -8.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. CNS Pharmaceuticals has a P/B Ratio of 16.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here